文献速递脑血管病认知障碍与痴呆

加速生物学衰老与脑小血管病存在及纵向进展的关联

Associations of Accelerated Biological Aging With the Presence and Longitudinal Progression of Cerebral Small Vessel Disease.
PubMed 文献 · Neurology · 2026-04-10

该研究基于人群队列,在基线和随访时进行脑MRI,使用PhenoAge、Klemera-Doubal法和稳态失调三种方法估算生物学年龄。结果显示,较高的生物学年龄残差(尤其是KDMAge和PhenoAge)与脑小血管病负担及进展相关,特别是新发腔隙灶和新发脑微出血。

要点

  • KDMAge残差与脑小血管病总负担进展相关(OR=1.18)。
  • KDMAge残差与新发腔隙灶(OR=1.31)和新发脑微出血(OR=1.13)相关。
  • PhenoAge残差结果与KDMAge一致,HDAge残差无显著关联。

核心结论

  • 生物学年龄残差(尤其KDMAge和PhenoAge)与脑小血管病进展风险升高相关,尤其是新发腔隙灶和新发脑微出血。

研究设计与样本

  • 基于人群的Polyvascular Evaluation for Cognitive Impairment and Vascular Events队列研究。
  • 基线共3050名参与者(平均年龄61.22±6.67岁,女性53.51%),2662人完成中位4.7年的随访MRI。
  • 使用PhenoAge、Klemera-Doubal法和稳态失调三种方法估算生物学年龄。

主要发现

  • 较高的生物学年龄残差(尤其KDMAge和PhenoAge残差)与基线和随访时更高的脑小血管病负担相关。
  • KDMAge残差与脑小血管病总负担进展相关(OR=1.18,95%CI 1.08-1.30,p=0.001)。
  • KDMAge残差与新发腔隙灶相关(OR=1.31,95%CI 1.13-1.51,p<0.001)。
  • KDMAge残差与新发脑微出血相关(OR=1.13,95%CI 1.01-1.25,p=0.028)。
  • KDMAge残差与基底节区扩大的血管周围间隙进展或白质高信号进展无显著关联。

关键数值与推荐

  • KDMAge残差与脑小血管病总负担进展的OR=1.18(95%CI 1.08-1.30,p=0.001)。
  • KDMAge残差与新发腔隙灶的OR=1.31(95%CI 1.13-1.51,p<0.001)。
  • KDMAge残差与新发脑微出血的OR=1.13(95%CI 1.01-1.25,p=0.028)。
  • PhenoAge残差结果与KDMAge残差一致;HDAge残差与脑小血管病进展无显著关联。

临床怎么用

  • 基于生物标志物的生物学年龄残差可能有助于识别临床相关脑小血管病进展风险较高的个体。

局限性

  • 需要更长的随访时间和更多样化的队列来验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cerebral small vessel disease (CSVD) is a major cause of dementia and stroke, typically identified by lesions such as white matter hyperintensity (WMH), lacunes, cerebral microbleeds (CMBs), enlarged perivascular spaces, and brain atrophy. Biomarker-based biological age (BA), derived from routinely measured clinical indicators and largely reflecting vascular and metabolic physiologic burden, may provide complementary information beyond chronological age. The aim of this study was to investigate the associations between BA residual and both the presence and progression of CSVD and its neuroimaging manifestations. METHODS: In the population-based Polyvascular Evaluation for Cognitive Impairment and Vascular Events cohort, participants underwent brain magnetic resonance imaging (MRI) at baseline (2017-2019) and at follow-up (2022-2024). BA was estimated using 3 established methods: PhenoAge, Klemera-Doubal method, and homeostatic dysregulation. Progression of CSVD and its imaging markers, including new lacunes, new CMBs, progression of enlarged perivascular spaces in the basal ganglia (BG-EPVS), and progression of WMHs, was assessed. Associations between BA residual and progression of CSVD were analyzed using logistic or ordinal logistic regression models, as appropriate. RESULTS: A total of 3,050 participants were included at baseline (mean age 61.22 ± 6.67 years; 53.51% female); 2,662 completed follow-up MRI over a median of 4.7 years, and 388 were lost to follow-up. Higher BA residual, particularly KDMAge and PhenoAge residual, was associated with greater CSVD burden at baseline and follow-up. Moreover, KDMAge residual was positively associated with the progression of total CSVD burden (odds ratio [OR] = 1.18, 95% CI 1.08-1.30; p = 0.001), new lacunes (OR = 1.31, 95% CI 1.13-1.51, p < 0.001), and new CMBs (OR = 1.13, 95% CI 1.01-1.25; p = 0.028), but not with progression of BG-EPVS or WMHs at follow-up. PhenoAge residual showed results consistent with those of KDMAge residual, whereas HDAge residual showed no significant association with progression of CSVD or its imaging markers. DISCUSSION: This community-based cohort study demonstrated that BA residuals, particularly KDMAge and PhenoAge, were associated with higher odds of CSVD progression, especially with development of new lacunes and new CMBs. Biomarker-based BA residual may help identify individuals at higher risk of clinically relevant CSVD progression. Future studies with longer follow-up periods and more diverse cohorts are warranted to validate these findings.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Wang M, Cai X, Gao P, et al. Associations of Accelerated Biological Aging With the Presence and Longitudinal Progression of Cerebral Small Vessel Disease. Neurology. 2026. PMID: 41962120. doi:10.1212/WNL.0000000000214818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。